ACT1_3A: ACT1, figure 3A
In raredd/kmdata: A Database of Reconstructed Individual Patient Level Data from Oncology Clinical Trials
ACT1_3A R Documentation
ACT1, figure 3A
Description
Kaplan-Meier digitized data from ACT1, figure 3A (PMID 25385727). A reported sample size of 637 for a primary endpoint of OS in lung cancer.
Usage
ACT1_3A
Format
A data frame of 637 observations and 3 variables:
time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (amrubicin, topotecan)
Source
von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of
amrubicin versus topotecan as second-line treatment for patients with
small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9.
Examples
summary(ACT1_3A)
kmplot(ACT1_3A)
raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| ACT1_3A | R Documentation |
ACT1, figure 3A
Description
Kaplan-Meier digitized data from ACT1, figure 3A (PMID 25385727). A reported sample size of 637 for a primary endpoint of OS in lung cancer.
Usage
ACT1_3A
Format
A data frame of 637 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0: no event, 1: event) |
|
arm | treatment arms (amrubicin, topotecan) | |
Source
von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9.
Examples
summary(ACT1_3A)
kmplot(ACT1_3A)
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.